|| Checking for direct PDF access through Ovid
(Anesth Analg. 2017;124(4):1208–1210)Currently, there is no standardized protocol regarding the optimal administration, dosing strategy, and maternal monitoring requirements of intravenous (IV) remifentanil for labor analgesia. As this drug has the potential to cause sedation, respiratory depression, oxygen desaturation, and more, it is essential that clear recommendations are established. The authors of the present study surveyed and evaluated current practices for IV remifentanil administration for labor analgesia across academic medical centers in the United States.